鹿得医疗(832278) - 2022 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders for the first nine months of 2022 was CNY 27,983,931.23, down 16.85% from CNY 33,654,862.00 in the same period last year[14] - Operating income for the third quarter of 2022 was CNY 79,321,240.17, a decrease of 6.16% compared to CNY 84,530,290.27 in the third quarter of 2021[15] - Total operating revenue for 2022 was CNY 79,321,240.17, a decrease from CNY 84,530,290.27 in 2021, representing a decline of approximately 14.5%[50] - Operating profit for 2022 was CNY 12,528,738.42, compared to CNY 10,820,053.06 in 2021, showing an increase of approximately 15.8%[51] - Total profit for Q3 2022 was ¥12,956,172.46, compared to ¥8,166,114.36 in Q3 2021, marking an increase of approximately 58.5%[56] - Net profit for Q3 2022 was ¥11,724,611.31, compared to ¥7,368,150.24 in Q3 2021, indicating a significant increase of about 59.5%[56] Assets and Liabilities - Total assets as of September 30, 2022, were CNY 469,487,978.68, a decrease of 2.83% compared to the end of the previous year[14] - The company's total liabilities to assets ratio decreased to 18.48% from 24.90% year-on-year[14] - The balance of trading financial assets increased by 1,387.65% to CNY 22,319,846.80 due to investments in low-risk financial products[16] - The balance of short-term loans increased by 100% to CNY 1,000,188.89, reflecting the company's strategy to enhance short-term liquidity[16] - The total liabilities decreased from 120,322,340.34 yuan at the end of 2021 to 86,753,924.53 yuan by September 30, 2022[44] - Current liabilities decreased from CNY 107,647,995.92 to CNY 74,085,226.27, reflecting a reduction of approximately 31.2%[48] Cash Flow - The company's cash flow from operating activities increased by 262.76% to CNY 14,623,600.62 in the third quarter of 2022, compared to a negative cash flow of CNY 8,985,002.94 in the same period last year[15] - Net cash flow from operating activities was CNY 9,791,528.46, up from CNY 5,921,715.03 year-over-year[60] - Cash inflow from operating activities totaled CNY 280,527,634.84, while cash outflow was CNY 270,736,106.38, resulting in a net cash flow of CNY 9,791,528.46[60] - Cash flow from investment activities showed a net outflow of CNY 43,514,417.01, compared to a net inflow of CNY 44,482,868.54 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY 5,356,277.00, down from a net inflow of CNY 13,100,000.00 in the previous year[60] Shareholder Information - Total shares outstanding are 176,000,000, with 72,988,400 shares (41.47%) being unrestricted and 103,011,600 shares (58.53%) being restricted[28] - The largest shareholder, Xiang Youliang, holds 39,130,000 shares, representing 22.23% of total shares[30] - The second largest shareholder, Shanghai Lude Industrial Development Co., Ltd., holds 38,944,000 shares, accounting for 22.13%[30] - The company has a total of 7,913 common stock shareholders[28] Research and Development - Research and development expenses for 2022 were CNY 9,609,396.31, up from CNY 8,667,604.26 in 2021, indicating an increase of about 10.9%[51] - Research and development expenses for the first nine months of 2022 totaled ¥9,609,396.31, an increase from ¥8,667,604.26 in the same period of 2021, showing a growth of about 10.8%[55] Other Income and Expenses - Other income for the first nine months of 2022 was ¥3,704,407.43, an increase of 461.37% compared to the same period last year, mainly due to government subsidies received in September 2022[22] - Financial expenses for the first nine months of 2022 were -¥11,454,795.66, a decrease of 993.98% compared to the same period last year, primarily due to exchange rate gains[22] - The income tax expense for the first nine months of 2022 was ¥3,278,613.02, a decrease of 32.37% compared to the same period last year, mainly due to changes in R&D tax deduction policies[22] Legal and Compliance - The company is involved in a legal dispute with Sunshine Property Insurance Co., Ltd. regarding a compensation claim of 1,137,045.59 yuan[36] - The company has reported no significant adverse effects from ongoing litigation, which is considered normal for business operations[35] - The company has disclosed its compliance with internal review procedures for significant events during the reporting period[34]